SCHEMBL21724372

SCHEMBL21724372

CC(C(F)F)n1cnnc1-c1cccc(N)n1

nearest known ligand 0.48

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 19/20 0.48
RET P07949 1/20 0.42
CDK2 P24941 1/20 0.42
ITK Q08881 1/20 0.42
MERTK Q12866 1/20 0.42
PRKAA1 Q13131 1/20 0.42
ROCK1 Q13464 1/20 0.42
MAP3K7 O43318 1/20 0.40
MAP3K6 O95382 1/20 0.40
MAP4K1 Q92918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21724101 0.89 MAP3K5 (0.45) MAP3K5RETCDK2ITKMERTK
SCHEMBL21724100 0.89 MAP3K5 (0.45) MAP3K5RETCDK2ITKMERTK
SCHEMBL29506348 0.85 MAP3K5 (0.56) MAP3K5RETCDK2ITKMERTK
SCHEMBL15136088 0.85 MAP3K5 (0.56) MAP3K5RETCDK2ITKMERTK
SCHEMBL23064233 0.83 MAP3K5 (0.45) MAP3K5RETCDK2ITKMERTK
SCHEMBL21724355 0.82 MAP3K5 (0.52) MAP3K5RETCDK2ITKMERTK
SCHEMBL20501035 0.82 MAP3K5 (0.58) MAP3K5RETCDK2ITKMERTK
SCHEMBL20501037 0.82 MAP3K5 (0.58) MAP3K5RETCDK2ITKMERTK
SCHEMBL21723822 0.82 MAP3K5 (0.52) MAP3K5RETCDK2ITKMERTK
SCHEMBL21724058 0.82 MAP3K5 (0.52) MAP3K5RETCDK2ITKMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404263-B2 ASK1 inhibiting agents BIOGEN MA INC. (US) 2025-09-02 US disclosed
US-11999715-B2 ASK1 inhibiting agents BIOGEN MA INC. (US) 2024-06-04 US disclosed
US-20240109867-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2024-04-04 US disclosed
US-11814362-B2 ASK1 inhibiting agents BIOGEN MA INC. (US) 2023-11-14 US disclosed
US-11814362-B2 ASK1 inhibiting agents BIOGEN MA INC. (US) 2023-11-14 US disclosed
US-11814362-B2 ASK1 inhibiting agents BIOGEN MA INC. (US) 2023-11-14 US disclosed
EP-3837251-B1 ASK1 INHIBITING AGENTS BIOGEN MA INC (US) 2023-06-21 EP disclosed
EP-3837251-B1 ASK1 INHIBITING AGENTS BIOGEN MA INC (US) 2023-06-21 EP disclosed
US-20210317103-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2021-10-14 US disclosed
US-20210317103-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2021-10-14 US disclosed
CN-113227070-A ASK1 inhibitors 比奥根MA公司 2021-08-06 CN disclosed
EP-3837251-A1 ASK1 INHIBITING AGENTS Biogen MA Inc. (US) 2021-06-23 EP disclosed
EP-3814333-A1 ASK1 INHIBITING AGENTS Biogen MA Inc. (US) 2021-05-05 EP disclosed
US-20210115020-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2021-04-22 US disclosed
US-20210115020-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. 2021-04-22 US disclosed
CN-112638896-A ASK1 inhibitors 比奥根MA公司 2021-04-09 CN disclosed
WO-2020036949-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. (US) 2020-02-20 WO disclosed
WO-2020036949-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. (US) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317103-A1 ASK1 INHIBITING AGENTS MAP3K1, MAP3K6, MAP3K10 MAP3K5 10/4885RET 585/4885CDK2 275/4885
US-20210115020-A1 ASK1 INHIBITING AGENTS MAP3K1, MAP3K10, MAP3K20 MAP3K5 12/4885RET 894/4885CDK2 342/4885
US-12404263-B2 ASK1 inhibiting agents MAP3K1, MAP3K10, MAP3K20 MAP3K5 12/4885RET 894/4885CDK2 342/4885
US-11999715-B2 ASK1 inhibiting agents MAP3K1, MAP3K6, MAP3K10 MAP3K5 10/4885RET 585/4885CDK2 275/4885
US-11814362-B2 ASK1 inhibiting agents MAP3K1, MAP3K10, MAP3K20 MAP3K5 12/4885RET 894/4885CDK2 342/4885
US-20240109867-A1 ASK1 INHIBITING AGENTS MAP3K1, MAP3K10, MAP3K20 MAP3K5 12/4885RET 894/4885CDK2 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.